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Abstract 
  Intracerebral hemorrhage represents stroke characterized by formation and expansion of 
hematoma within brain parenchyma.  Blood-derived factors released from hematoma are 
considered to be involved in poor prognosis of this disorder.  We previously reported that 
thrombin, a blood-derived serine protease, induced cytotoxicity in the cerebral cortex and the 
striatum in organotypic slice cultures, which depended on mitogen-activated protein kinase 
(MAPK) pathways.  Here we investigated the mechanisms of thrombin cytotoxicity in the 
striatum in vivo.  Thrombin microinjected into the striatum of adult rats induced neuronal 
death and microglial activation around the injection site.  Neuronal loss without any sign of 
nuclear fragmentation was observed as early as 4 h after thrombin injection, which was 
followed by gradual neuronal death exhibiting nuclear fragmentation.  Thrombin-induced 
damage assessed at 72 h after injection was partially but significanty reduced by concomitant 
administration of inhibitors of MAPK pathways.  Activation of extracellular signal-regulated 
kinase (ERK) and p38 MAPK in response to thrombin was verified by western blot analysis.  
Moreover, phosphorylated ERK and p38 MAPK were localized prominently in reactive 
microglia, and inhibition of microglial activation by minocycline attenuated thrombin-induced 
damage, suggesting that reactive microglia were responsible for thrombin-induced neuronal 
death.  Thus, MAPK pathways and microglial activation may serve as therapeutic targets of 
pathogenic conditions associated with hemorrhagic stroke. 
 
Keywords: apoptosis, intracerebral hemorrhage, microglia, microinjection, striatum 
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  Intracerebral hemorrhage (ICH) represents approximately 15% of all strokes.  Undesirable 
prognosis due to the lack of efficient therapeutic interventions makes ICH a serious clinical 
problem (Fayad and Awad, 1998).  Ganglionic hemorrhages are the most common forms of 
ICH, followed by lobar ones (Xi et al., 2006).  While physical trauma and mass effect could 
participate in brain damage after hemorrhagic events (Sinar et al., 1987), accumulating 
evidence demonstrates that brain edema after ICH is caused by hematoma-derived 
components (Huang et al., 2002; Sansing, et al., 2003) including thrombin (Lee et al., 1996; 
Kitaoka et al., 2002). 
  Thrombin is a blood-derived serine protease essential to coagulation and is abundantly 
present in hematoma.  Uncontrolled thrombin activity after ICH could cause neuronal cell 
death as well as brain edema.  For example, evidence has shown that thrombin induces cell 
death with characteristics of apoptosis in cultured neurons and astrocytes (Donovan et al., 
1997) and that intrastriatal injection of thrombin increases apoptotic cells and causes brain 
damage (Xue and Del Bigio, 2001).  Moreover, in vitro and in vivo studies have 
demonstrated that thrombin activates microglial cells in the midbrain, thereby causing 
dopaminergic neuronal death (Choi et al., 2003; Katsuki et al., 2006). 
  Despite increasing amount of information on thrombin and ICH, few studies have 
addressed the mechanisms of neuronal damage after ICH in the striatum.  In this context, we 
have previously reported that thrombin induces shrinkage of the striatal tissue in organotypic 
cortico-striatal slice cultures.  The tissue shrinkage was dependent on activation of microglia 
and mitogen-activated protein kinase (MAPK) pathways (Fujimoto et al., 2006).  Based on 
these findings, here we examined the mechanisms of cytotoxicity of thrombin microinjected 
into the striatum of adult rats, with special reference to microglia and MAPKs. 
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Experimental procedures 
Drugs and chemicals 
  Drugs and chemicals were obtained from Nacalai Tesque (Kyoto, Japan), unless otherwise 
indicated.  Thrombin from bovine plasma (catalog No. T4648 and T3399), bovine serum 
albumin (catalog No. A2153) and minocycline hydrochloride were obtained from Sigma (St. 
Louis, MO, USA).  Argatroban was from Sawai Pharmaceutical (Osaka, Japan).  PD98059 
and SB203580 were from Calbiochem (San Diego, CA, USA).  SP600125 was from Tocris 
Cookson (Bristol, UK). 
 
Surgical procedures and drug administration 
  Male Sprague-Dawley rats initially weighing 220 - 280 g were used.  Animals were kept 
at constant ambient temperature (24 ± 1 °C) under a 12-h light and dark cycle with free access 
to food and water.  Experiments were conducted in accordance with the ethical guidelines of 
Kyoto University animal experimentation committee, and the guidelines of the Japanese 
Pharmacological Society.  Drug administration was performed according to a previous report 
(Xue and Del Bigio, 2001) with modification.  Briefly, rats were anesthetized with 
pentobarbital (50 mg/kg, i.p., Dainippon Sumitomo Pharmaceutical, Osaka, Japan) and placed 
in a stereotaxic frame (Narishige, Tokyo, Japan).  After scalp incision, a hole was drilled on 
the skull.  For intrastriatal injection, each rat was unilaterally implanted with a stainless steel 
guide cannula (o.d. 0.7 mm) above the right striatum (0.2 mm anterior, 3.0 mm lateral from 
bregma).  The guide cannula was held firmly in place by dental acrylic cement (Nisshin 
Dental Products Inc., Kyoto, Japan).  Drugs were administered via a stainless steel injection 
cannula (o.d. 0.35 mm), whose tip was inserted 6.0 mm below the surface of the skull.  Drug 
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solution in a volume of 5 μl/rat was infused at a constant rate of 0.5 μl/min.  Unless 
otherwise indicated, thrombin (catalog No. T4648, Lot 023K7602, 24.5 U/mg solid) dissolved 
in saline at 4000 U/ml (163 mg/ml) was used, where thrombin activity was expressed by NIH 
units.  The injection cannula was left in place for at least additional 5 min to prevent 
backflow of drugs.  Minocycline was given intraperitoneally at a dose of 45 mg/kg at 1 and 
13 h after thrombin injection, and at 22.5 mg/kg at 25, 37 and 49 h.  These doses 
approximate those used in a study on experimental intracerebral hemorrhage (Power et al., 
2003).  Control rats received intraperitoneal injection of the equivalent volume of saline. 
 
Histological examination 
  After indicated periods from intrastriatal injection, rats were anesthetized again and 
perfused through the heart with phosphate buffered saline (PBS) followed by 4% 
paraformaldehyde.  Brains were removed and postfixed in 4% paraformaldehyde and 
dehydrated with 15% sucrose solution for overnight at 4°C.  After freezing, coronal brain 
sections (16 μm) containing the injection site were prepared and mounted onto slides.  They 
were then subjected to nuclear staining or to immunohistochemistry.  Cell nuclei were 
stained with Hoechst 33342 (0.1 mg/ml, Molecular Probes, Eugene, OR, USA) for 1 h at 
room temperature and visualized by ultraviolet illumination.  For immunohistochemitry, 
specimens were autoclaved (121°C for 15 min) for epitope retrieval.  After rinse with PBS, 
they were permeabilized and blocked with 0.5% Triton X-100 in PBS containing 1.5% horse 
serum or goat serum for 1 h at room temperature.  Specimens were then incubated with 
primary antibodies overnight at 4°C.  Primary antibodies were mouse anti-NeuN (1:200, 
Chemicon International, Temecula, CA, USA), mouse anti-OX42 (1:300, Dainippon 
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Pharmaceutical, Osaka, Japan), rabbit anti-phospho-p44/42 MAP kinase (T202/Y204) (1:250, 
Cell Signaling Technology, Beverly, MA, USA), rabbit anti-phospho-p38 MAP kinase 
(T180/Y182) (1:250, Cell Signaling Technology) and rabbit anti-iNOS (1:250, BD 
Transduction Laboratories, San Diego, CA, USA).  For immunohistochemistry with 
anti-OX42 antibody, epitope retrieval was not performed.  After rinse with PBS, specimens 
were incubated with secondary antibodies for 1 h at room temperature.  Alexa Fluor 
568-labeled goat anti-rabbit IgG (1:200, Molecular Probes), Alexa Fluor 488-labeled goat 
anti-mouse IgG (1:200, Molecular Probes) and biotinylated horse anti-mouse IgG (1:200, 
Vector Laboratories, Burlingame, CA, USA) were used as secondary antibodies.  After 
incubation with the biotinylated secondary antibody, specimens were treated with 
avidin-biotinylated horseradish peroxidase complex (Vectastain Elite ABC kit, Vector 
Laboratories), and then peroxidase was visualized with 0.07% diaminobenzidine and 0.018% 
H2O2.  Bright-field images were captured through a monochrome chilled CCD camera 
(C5985; Hamamatsu Photonics, Hamamatsu, Japan) and stored as image files.  We defined 
the striatal region without NeuN-positive cells as the injured region, and measured the injured 
area with NIH Image 1.63.  Fluorescence signals were observed with a laser-scanning 
confocal microscopic system (MRC1024, Biorad, Hercules, CA, USA). 
 
Western blot analysis 
  After indicated periods from thrombin injection, the striatal tissue including the injection 
site was harvested and homogenized in ice-cold lysis buffer containing 20 mM Tris–HCl (pH 
7.0), 25 mM β-glycerophosphate (Sigma), 2 mM EGTA•2Na, 1% Triton X-100, 1 mM 
vanadate, 1% aprotinin (Sigma), 1 mM phenylmethylsulfonyl fluoride and 2 mM 
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dithiothreitol.  The contralateral striatum was also harvested as a control in several 
experiments.  Samples were mixed with a sample buffer composed of 124 mM Tris–HCl (pH 
6.8), 4% sodium dodecyl sulfate (SDS), 10% glycerol, 0.02% bromophenol blue and 4% 
2-mercaptoethanol.  After boiling for 5 min, samples were subjected to 12% 
SDS-polyacrylamide gel electrophoresis for 70 min, followed by transfer to PVDF membrane 
(Millipore, Bedford, MA, USA) for 70 min.  Membranes were blocked for at least 1 h by 5% 
nonfat milk at room temperature and subsequently incubated overnight with mouse 
anti-phospho-p44/42 MAP kinase (T202/Y204) (1:2000, Cell Signaling Technology), rabbit 
anti-p44/42 MAP kinase (1:1000, Cell Signaling Technology), rabbit anti-phospho-p38 MAP 
kinase (1:500, Cell Signaling Technology), rabbit anti-p38 MAP kinase (1:1000, Cell 
Signaling Technology) and mouse anti-β-actin (1:50000, Sigma).  The membranes were 
rinsed and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (1:10000, 
Jackson Immunoresearch Laboratories, West Grove, PA, USA) and goat anti-rabbit IgG 
(1:10000, Jackson Immunoresearch Laboratories).  After incubation with secondary 
antibodies, membranes were rinsed and bound antibodies were detected with enhanced 
chemiluminescence kit (Amersham Biosciences, Buckinghamshire, UK) according to the 
manufacturer's instructions.  The band intensities were analyzed with NIH image 1.63. 
 
Statistics 
  Data are expressed as means ± SEM.  Statistical significance of difference was evaluated 
with Student t-test, or with one-way analysis of variance followed by 
Student–Newman–Keuls' test for multiple comparisons.  Probability values less than 5% 
were considered significant. 
8 
Results 
Thrombin induces striatal neuronal death and microglial activation 
  We injected thrombin into the right striatum of adult rats and examined brain sections 
immunostained with anti-NeuN antibody (Fig. 1).  The number of neurons around the 
injection site started to decrease 4 h after thrombin injection (Fig. 1D and E).  Thereafter, the 
number of neurons progressively decreased and only few neurons were alive after 72 h of 
thrombin injection (Fig. 1K and M).  To visualize morphology of cell nuclei, several brain 
sections were stained with Hoechst 33342.  At 4 h after thrombin injection, cell nuclei 
around the injection site exhibited no sign of nuclear fragmentation (Fig. 1F).  In contrast, 
several fragmented nuclei were found after 24 h and 72 h of thrombin injection in areas 
peripheral to the injection site (Fig. 1I andL).  Immunohistochemistry on brain sections 
obtained after 72 h of thrombin injection revealed that there were very few NeuN-positive 
cells around the injection site, and we could easily distinguish the border between regions 
with or without NeuN immunoreactivity (Fig. 1J).  Accordingly, we evaluated the degree of 
cytotoxicity by the injured area defined as a region without NeuN immunoreactivity in the 
striatum.  Administration of 20 U thrombin (Sigma, catalog No. T4648, Lot 023K7602, 24.5 
U/mg solid) resulted in 3.44 ± 0.25 mm2 of injured area at 72 h (n=8).  Another thrombin 
preparation (Sigma, catalog No. T3399, Lot 045K7590, 51 U/mg solid) given at the same 
dose (20 U) induced a similar degree of injury (3.52 ± 0.29 mm2 of injured area at 72 h, n=4).  
In contrast, we did not observe changes in NeuN immunoreactivity or nuclear morphology 
when we injected bovine serum albumin at a concentration of the protein equivalent to 
thrombin T4648 solution (0.816 mg in 5 μl saline, data not shown).  In addition, argatroban 
(2.5 μg mixed in thrombin solution), a thrombin inhibitor, significantly reduced thrombin 
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toxicity (2.43 ± 0.28 mm2 of injured area, n=8; P=0.017 vs. thrombin T4648 alone).  These 
results suggest that thrombin induces necrotic neuronal death shortly after injection, as well as 
delayed apoptotic neuronal degeneration. 
  Contrary to the loss of NeuN immunoreactivity, thrombin injection caused drastic 
augmentation of immunoreactivity for OX42, a marker protein of microglia.  At the injection 
site, microglia changed their morphology from ramified shape into activated amoeboid shape 
at 4 h after thrombin injection.  At 72 h, thrombin-injected striatum was occupied by a 
markedly increased number of activated microglia, whereas microglia retained their 
population and ramified appearance in the contralateral striatum (Fig. 2B-D).  Some but 
fewer microglia showing amoeboid morphology were observed in the saline-injected striatum, 
which probably resulted from mechanical damage caused by needle insertion (Fig. 2A).  
Nevertheless, the number of activated microglia in thrombin-injected striatum increased 
approximately 10 times larger than that in saline-injected striatum (3374 ± 408 vs. 312 ± 40 
cells/section, n=4 for each condition, P=0.005).  These results suggest that thrombin induces 
microglial proliferation and activation in the striatum. 
 
MAPKs are involved in thrombin-induced striatal neuronal death 
  We previously showed that inhibition of MAPK pathways perturbed thrombin-induced 
striatal shrinkage in organotypic slice cultures (Fujimoto et al., 2006).  Therefore we 
examined the effects of inhibitors of MAPK pathways on thrombin cytotoxicity in vivo.  We 
used PD98059 (5 nmol), a MAPK kinase inhibitor, SB203580 (5 nmol), a p38 MAPK 
inhibitor, and SP600125 (5 nmol), a c-Jun N-terminal kinase (JNK) inhibitor.  Vehicle (saline 
with DMSO as solvent) or MAPK inhibitors were mixed with thrombin solution and the 
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mixture was injected into the striatum.  We found that all of these inhibitors were 
neuroprotective against thrombin cytotoxicity.  The protective effects were manifested by 
significant reduction of the injured area (Fig. 3).  A clear border between the injured area and 
the intact area was observed also in the striatum treated with thrombin plus MAP kinase 
inhibitors, and MAPK inhibitors did not increase the number of NeuN-positive cells within 
the injured area.  The density of NeuN-positive cells in the contralateral striatum in the brain 
section prepared from thrombin-injected rats was 1172 ± 33 cells/mm2 (n=9), and 
thrombin-induced decrease of NeuN immunoreactivity corresponded to the loss of 4330 ± 321 
neurons/section.  Likewise, the numbers of NeuN-positive cells lost after treatment with 
thrombin plus PD98059, SB203580 and SP600125 were estimated to be 3492 ± 239 (n=9), 
3220 ± 209 (n=8) and 3451 ± 223 (n=8) cells/mm2, respectively, all of which were 
significantly smaller (P<0.05) than that after treatment with thrombin. 
  To further clarify the involvement of MAPK pathways, we examined the phosphorylation 
level of MAPKs by western blot analysis.  Phosphorylated extracellular signal regulated 
kinase (ERK) increased promptly after thrombin injection and declined thereafter, whereas 
phosphorylated p38 MAPK increased gradually, which was accompanied by an increase in 
total p38 MAPK (Fig. 4A-C).  To determine cell types exhibiting ERK phosphorylation after 
4 h of thrombin injection, we performed double immunofluorescence with combination of 
antibodies against phosphorylated ERK and cell type-specific marker proteins.  
Immunostaining revealed that most of phosphorylated ERK-positive cells were microglia (Fig. 
4D).  We also tried to identify cells that express phosphorylated p38 MAPK in brain sections 
obtained after 72 h of thrombin injection.  As shown in Fig. 4E, phosphorylated p38 MAPK 
also colocalized with OX42, a marker of microglia. 
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  We further examined the involvement of reactive microglia in thrombin neurotoxicity.  
After thrombin injection into the striatum, minocycline, an inhibitor of microglial activation 
(Power et al., 2003), or saline was intraperitoneally administered.  Minocycline treatment 
significantly reduced the number of reactive microglia around the injection site (Fig. 5A) and 
the injured area (Fig. 5B).  Moreover, double immunofluorescence with antibodies against 
inducible nitric oxide synthase (iNOS) and OX42 revealed that some reactive microglia 
expressed iNOS after 24 h of thrombin injection in the ipsilateral striatum but not in the 
contralateral side (Fig. 5C, D).  These results suggest that reactive microglia are responsible 
for thrombin neurotoxicity. 
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Discussion 
  Thrombin induces neuronal loss in vitro (Donovan et al., 1997; Katsuki et al., 2006) and in 
vivo (Xue and Del Bigio, 2001; Choi et al., 2003).  The detrimental effects of thrombin are 
considered to be one of the major causes of ICH-induced neurologic deficits (Gingrich and 
Traynelis, 2000; Xi et al., 2003).  Thus the regulation of thrombin cytotoxicity could have a 
therapeutic potential for ICH (Kitaoka et al., 2002).  In previous work on cortico-striatal 
slice cultures, we demonstrated that thrombin induces apoptotic neuronal death with a long 
delay (Fujimoto et al., 2006).  Here we investigated whether delayed apoptotic neuronal 
death occurs in adult rat striatum in response to thrombin.  Predictably, thrombin induced 
neuronal loss around the injection site in the striatum.  Two thrombin preparations with 
different purities induced a similar degree of injury when administered at the same dosage of 
total activity.  In addition, thrombin toxicity was significantly attenuated by a thrombin 
inhibitor, argatroban.  Previous results in vitro also showed that cytotoxicity of thrombin in 
the striatal tissue was blocked by prior heat-inactivation or by co-application of argatroban 
(Fujimoto et al., 2006).  Overall, our observations indicate that proteolytic activity 
contributes to the neurotoxicity of thrombin in the striatum, although the involvement of 
non-proteolytic potential of thrombin preparation could not be entirely ruled out (Weinstein et 
al., 2005). 
  Unexpectedly, thrombin reduced the number of NeuN-positive cells around the injection 
site as early as 4 h of injection.  This acute loss of neurons may result from necrotic death of 
some neuronal populations (Xue and Del Bigio, 2001), because we did not observe any cell 
nuclei undergoing fragmentation at 4 h after thrombin injection.  On the other hand, many 
fragmented nuclei were observed at 1 or 3 days after thrombin injection, suggesting that the 
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loss of NeuN-positive cells in later days is a consequence of apoptotic neuronal death.  
Consistent with our observations, a previous report has demonstrated that apoptotic cells do 
not increase at 6 h after thrombin infusion (Gong et al., 2001).  Our results are also in 
agreement with the time window of delayed thrombin- and ICH-induced apoptosis 
(Matsushita et al., 2000; Gong et al., 2001; Xue and Del Bigio, 2001).  We did not examine 
the effect of caspase inhibitors against thrombin neurotoxicity, because we found previously 
that a caspase-3 inhibitor had no effect on thrombin cytotoxicity in cortico-striatal slice 
cultures (Fujimoto et al., 2006). 
  In the present study, phosphorylation of ERK was found in the ipsilateral striatum at 4 h 
after thrombin injection.  Prompt ERK phosphorylation is consistent with our previous 
findings in vitro (Fujimoto et al., 2006; Katsuki et al., 2006).  In addition, blockade of ERK 
pathway by PD98059 could reduce thrombin-induced loss of neurons, as reflected by the 
decrease in the injured area.  These results suggest that ERK pathway participates in 
thrombin neurotoxicity in the striatum.  We also detected a gradual increase in the level of 
phosphorylated p38 MAPK after thrombin injection.  Interestingly, however, 
phosphorylation of p38 MAPK was accompanied by elevation of total p38 MAPK protein 
level.  It is thus plausible that elevated level of phosphorylated p38 MAPK was a 
consequence of an increase in p38 MAPK itself.  Nevertheless, inhibition of p38 MAPK by 
SB203580 decreased thrombin-induced injury, indicating that p38 MAPK pathway is also 
involved in thrombin-induced neuronal death in the striatum.  Together with the protective 
effect of a JNK inhibitor SP600125, our present results demonstrated that ERK, p38 MAPK 
and JNK are all involved in thrombin-induced striatal damage in vivo.  These observations 
are consistent with our previous findings in vitro that PD98059, SB203580 and SP600125 all 
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suppressed thrombin-induced shrinkage of the striatal tissue in organotypic culture (Fujimoto 
et al., 2006).  PD98059 and SB203580 were also shown to attenuate thrombin-induced 
dopaminergic neuronal death in the midbrain in vivo (Choi et al., 2003).  On the other hand, 
SP600125 exacerbates, and SB203580 shows no effect on, thrombin-induced cortical injury in 
vitro (Fujimoto et al., 2006), suggesting differential involvement of MAPKs in the regulation 
of thrombin neurotoxicity between the cerebral cortex and the striatum.  Whether cortical 
injury induced by thrombin in vivo is regulated by MAPKs in a similar way to that in vitro 
remains to be determined. 
  Participation of reactive microglia in thrombin neurotoxicity has been reported in several 
studies (Choi et al., 2003; Katsuki et al., 2006).  Here we observed reactive microglia 
characterized by strong OX42 immunoreactivity with amoeboid appearance after thrombin 
injection.  Phosphorylation of ERK and p38 MAPK in these reactive microglia was also 
visible, which may be related to the detrimental effects of thrombin (Koistinaho and 
Koistinaho, 2002).  Moreover, thrombin-induced neuronal injury was reduced by 
administration of minocycline, an inhibitor of microglial activation (Power et al., 2003), 
consistent with deleterious actions of reactive microglia.  A plausible mechanism of the 
involvement of reactive microglia in neurotoxicity is that these cells may release cytokines 
and nitric oxide (Möller et al., 2000), which results from activation of NF-κB as a 
consequence of activation of MAPK pathways (Ryu et al., 2000; Suo et al., 2003).  Indeed, 
we demonstrated here that a subpopulation of reactive microglia in the striatum expressed 
iNOS after thrombin injection.  Whether nitric oxide production participates in the striatal 
neurotoxicity of thrombin in vivo remains to be determined, although we did not observe 
effective protection of the striatal tissue in vitro by an iNOS inhibitor against thrombin 
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toxicity (Fujimoto et al., 2006).  In this context, Choi et al. (2005) has demonstrated that 
intrahippocampal injection of thrombin induces microglial activation associated with 
expression of iNOS and NADPH oxidase, and that resultant increase in oxidative stress 
contributes to thrombin neurotoxicity. 
  Overall, we demonstrated that thrombin injected into the striatum caused neuronal damage, 
which in part involves a delayed phase of neuronal loss with apoptotic features.  Prominent 
activation of microglia exhibiting MAPK activation, as well as a significant protective effect 
of MAPK inhibitors, suggests that regulation of MAPK pathways and/or microglial activation 
could be a useful therapeutic intervention against hemorrhagic stroke. 
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Figure legends 
Fig. 1.  Thrombin-induced neuronal death and nuclear fragmentation.  Brains were 
transcardially fixed by 4% paraformaldehyde, and coronal cryosections were prepared.  
Shown are representative images of coronal sections immunostained with anti-NeuN antibody 
at low (A, D, G and J) and high (B, E, H and K) magnification and Hoechst 33342-stained 
sections (C, F, I and L).  The sections were prepared from brains at 72 h after saline injection 
(A-C), 4 h (D-F), 24 h (G-I) and 72 h (J-L) after thrombin injection.  Arrowheads in I and L 
indicate fragmented nuclei.  Scale bars, 1 mm (A, D, G and J), 100 μm (B, E, H and K) and 
20 μm (C, F, I and L).  (M) The number of NeuN-positive cells at the injection site, at 
indicated periods after saline and thrombin treatment.  n=4-6. 
 
Fig. 2.  Representative images of brain coronal sections immunostained with anti-OX42 
antibody.  Images are of the injection site at 72 h after saline (A), 4 h (B) and 72 h (C) after 
thrombin injection, and of the contralateral striatum at 72 h after thrombin injection (D).  
Scale bar, 20 μm. 
 
Fig. 3.  Effects of MAPK inhibitors administered by intrastriatal injection concomitant with 
thrombin.  (A-D) Representative images of NeuN-immunostained coronal sections prepared 
from brains after 72 h of injection of thrombin alone (20 U with DMSO, 1:3; A), thrombin 
plus PD98059 (5 nmol; B), SB203580 (5 nmol; C) and SP600125 (5 nmol; D).  Scale bar, 1 
mm.  (E) The degree of injury was determined by the area devoid of NeuN immunoreactivity 
in the striatum.  Vehicle (veh, DMSO diluted 1:3 with saline) was also injected as control.  
# P < 0.001 vs. vehicle, * P < 0.05 vs. thrombin alone, n=7-9. 
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 Fig. 4.  Thrombin-induced phosphorylation of ERK and p38 MAPK.  (A) Representative 
immunoblots showing ERK and p38 MAPK phosphorylation in response to thrombin.  After 
indicated periods of injection, homogenates were prepared from 2 mm-thick sections of 
ipsilateral (i) and contralateral (c) striatum containing the injection site, and lysates were 
subjected to western blot analysis with specific antibodies against phosphorylated ERK, total 
ERK, phosphorylated p38 MAPK, total p38 MAPK and β-actin.  (B) Time course of ERK 
phosphorylation.  Ratio of phosphorylated ERK vs. total ERK at each time point was 
calculated.  * P < 0.05 vs. saline (4 h), n=3.  (C) Time course of p38 upregulation.  Ratio 
of total p38 MAPK vs. β-actin at each time point was calculated (n=3).  (D) Confocal 
immunofluorescence images of phosphorylated ERK (left) and OX42 (center), and their 
merged image (right) after 4 h of thrombin injection.  (E) Confocal immunofluorescence 
images of phosphorylated p38 MAPK (left) and OX42 (center), and their merged image 
(right) after 72 h of thrombin injection.  Arrowheads in D and E indicate colocalization.  
Scale car, 20 μm. 
 
Fig. 5.  Involvement of activated microglia in thrombin neurotoxicity.  (A, B) Effect of 
minocycline (MINO) on the number of activated microglia at the injection site (A) and the 
area injured by thrombin (B).  MINO was intraperitoneally administered at a dose of 45 
mg/kg at 1 and 13 h after thrombin injection and 22.5 mg/kg at 25, 37 and 49 h.  n=5.  (C, 
D) Confocal immunofluorescence images of iNOS (red) and OX42 (green) at the ipsilateral 
(C) and the contralateral (D) striatum after 24 h of thrombin injection.  Arrowheads indicate 
iNOS-positive microglia.  Scale car, 10 μm. 
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